Inspire collaborates with Boston Children’s Hospital and the Ehlers Danlos Society on study about rare disease patient access to genomic medicine

February 25, 2022

Inspire recently published a poster highlighting the power of patient-driven data in advancing the understanding and treatment of rare diseases.

The poster highlights findings from a study led by Inspire along with Boston Children’s Hospital and the Ehlers Danlos Society, and was created using data collected from the Inspire community. The data was collected through surveys and online interactions between patients and caregivers, and analyzed to identify trends and insights related to genomic medicine in rare diseases.

The poster offers new insights related to the use of genomic medicine in rare diseases. For example, patients and caregivers reported a high level of interest in genetic testing and personalized medicine, but many also expressed concerns about the cost and availability of these treatments.

The poster also highlights the importance of patient education and communication in advancing the use of genomic medicine in rare diseases. Patients and caregivers reported a need for clear and accessible information about genetic testing and personalized medicine, as well as for more opportunities to share their experiences and learn from others in the rare disease community.

The publication of this poster represents a significant step forward in the use of patient-driven data to advance rare disease research and treatment. By highlighting the insights and experiences of patients and caregivers, the poster provides valuable information for researchers, healthcare providers, and policymakers working to improve the lives of those living with rare diseases.

View the poster presentation.